Clinical Trials

Clinical Trials

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

We are happy to present the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West has a virtual discussion with...
Cancer Journey:
Cancer Type:
We are happy to present the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West has a virtual discussion with...
Cancer Journey:
Cancer Type:
For this round of case based panel discussions, Dr. Jack West is joined by Drs. Heather Wakelee and Caroline McCoach. Dr. Wakelee is Professor of...
Cancer Journey:
Cancer Type:
Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding...
Cancer Journey:
Cancer Type:
,
,
,
,
The Global Resource for Advancing Cancer Education (GRACE), in partnership with Georgetown University Hospital is pleased to present the videos from the panel discussion "2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know".
Cancer Journey:
Cancer Type:

Articles

Dr. Ross Camidge discusses a clinical trial studying patients with advanced stage lung cancer to identify those who may respond to a drug called ponatinib. Both small cell and non small cell lung cancer patients may be eligible. http://bit.ly/UCponatinib
Cancer Journey:
Cancer Type:
Dr. Jack West reviews treatment options for patients with an EGFR activating mutation and acquired resistance but no T790M mutation, focusing on a clinical trial with the novel hypoxia-induced pan-HER inhibitor TH4000.
Cancer Journey:
Cancer Type:
Dr. Jack West summarizes the rationale for testing immune checkpoint inhibitors as a first line treatment for patients with advanced NSCLC and highlights details of two trials testing this question.
Cancer Journey:
Cancer Type:
Guest post by Dr. Cathy Pietanza, a board-certified medical oncologist at Memorial Sloan Kettering Cancer Center in New York. She specializes in cancers that arise in the lungs and cares for a large number of patients with small cell lung cancer (SCLC).
Cancer Journey:
Cancer Type:
Disease Learning:
Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.
Cancer Journey:
Cancer Type:

Community Forum

No Result Found